Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life

Successful adjuvant bi-weekly gemcitabine chemotherapy for pancreatic cancer without impairing patients’ quality of life

<p>Abstract</p> <p>Background</p> <p>Although adjuvant gemcitabine (GEM) chemotherapy for pancreatic cancer is standard, the quality of life (QOL) in those patients is still impaired by the standard regimen of GEM. Therefore, we studied whether mild dose-intensity adjuv...

Full description

Bibliographic Details
Main Authors: Toyama Yoichi, Yoshida Seiya, Saito Ryota, Kitamura Hiroaki, Okui Norimitsu, Miyake Ryo, Ito Ryusuke, Son Kyonsu, Usuba Teruyuki, Nojiri Takuya, Yanaga Katsuhiko
Format: Article
Language:English
Published: BMC 2013-01-01
Series:World Journal of Surgical Oncology
Subjects:
Pancreatic cancer
Adjuvant chemotherapy
Bi-weekly gemcitabine
Mild dose-intensity
Survival prolongation
Patient’s quality of life
QLQ-C30 and QLQ-PAN26
Online Access:http://www.wjso.com/content/11/1/3

Internet

http://www.wjso.com/content/11/1/3

Similar Items